Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$4.58
+2.3%
$5.02
$3.42
$7.20
$255.21M1.751.57 million shs708,073 shs
Ocugen, Inc. stock logo
OCGN
Ocugen
$0.97
+4.3%
$0.90
$0.52
$1.98
$279.47M4.184.60 million shs3.28 million shs
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$1.51
+2.7%
$1.48
$1.02
$7.89
$85.45M0.97407,484 shs185,958 shs
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
$6.05
+2.2%
$8.41
$3.50
$14.30
$285.36MN/A341,610 shs124,393 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
+2.35%+7.39%-14.80%+14.09%-6.63%
Ocugen, Inc. stock logo
OCGN
Ocugen
+4.27%-6.21%+13.43%+45.92%-41.10%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
+2.72%+2.03%-13.71%+37.27%-74.23%
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
+2.20%-14.18%-14.91%+41.03%+604,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.1881 of 5 stars
0.01.00.00.01.60.80.6
Ocugen, Inc. stock logo
OCGN
Ocugen
1.0196 of 5 stars
3.51.00.00.00.60.00.0
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
1.991 of 5 stars
3.51.00.00.00.03.30.6
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
3.00
Buy$6.00521.12% Upside
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
3.00
Buy$7.80416.56% Upside
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TCRX, ACB, OCGN, and ZYBT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00
6/24/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00
5/12/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $7.00
5/12/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
5/7/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $10.00
5/6/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$7.00
4/8/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$246.72M1.04$0.62 per share7.43$7.78 per share0.59
Ocugen, Inc. stock logo
OCGN
Ocugen
$4.05M69.65N/AN/A$0.10 per share9.66
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$2.82M30.30N/AN/A$4.26 per share0.35
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
$25.53M11.18N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$1.63M$0.1141.5910.40N/A1.32%0.13%0.10%8/6/2025 (Estimated)
Ocugen, Inc. stock logo
OCGN
Ocugen
-$54.05M-$0.19N/AN/AN/A-1,271.12%-223.00%-92.20%8/6/2025 (Estimated)
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$127.50M-$1.09N/AN/AN/A-2,974.08%-55.76%-36.56%8/11/2025 (Estimated)
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/AN/A0.00N/AN/AN/AN/AN/A

Latest TCRX, ACB, OCGN, and ZYBT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/18/2025Q4 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.11$0.07-$0.04-$0.24$88.85 million$63.34 million
5/12/2025Q1 2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$0.28-$0.26+$0.02-$0.26$1.62 million$2.17 million
5/9/2025Q1 2025
Ocugen, Inc. stock logo
OCGN
Ocugen
-$0.06-$0.05+$0.01-$0.05N/A$1.48 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
N/AN/AN/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
N/AN/AN/AN/AN/A
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.13
4.31
2.16
Ocugen, Inc. stock logo
OCGN
Ocugen
1.74
2.60
2.60
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
0.15
8.55
8.55
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Ocugen, Inc. stock logo
OCGN
Ocugen
10.27%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
82.83%
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/A

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Ocugen, Inc. stock logo
OCGN
Ocugen
4.42%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
4.35%
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,13056.21 million56.21 millionOptionable
Ocugen, Inc. stock logo
OCGN
Ocugen
80292.03 million279.12 millionOptionable
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
10056.59 million54.13 millionNot Optionable
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
27847.17 millionN/AN/A

Recent News About These Companies

Zhengye Biotechnology Holding Ltd
ZYBT Zhengye Biotechnology Holding Limited
Zhengye Biotechnology Holding Ltd.
Zhengye Biotechnology Holding Limited (ZYBT)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$4.58 +0.11 (+2.35%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$4.57 -0.01 (-0.22%)
As of 07/3/2025 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Ocugen stock logo

Ocugen NASDAQ:OCGN

$0.97 +0.04 (+4.27%)
Closing price 07/3/2025 03:55 PM Eastern
Extended Trading
$0.96 -0.01 (-0.93%)
As of 07/3/2025 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

TScan Therapeutics stock logo

TScan Therapeutics NASDAQ:TCRX

$1.51 +0.04 (+2.72%)
Closing price 07/3/2025 03:55 PM Eastern
Extended Trading
$1.51 0.00 (0.00%)
As of 07/3/2025 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Zhengye Biotechnology stock logo

Zhengye Biotechnology NASDAQ:ZYBT

$6.05 +0.13 (+2.20%)
As of 07/3/2025 01:00 PM Eastern

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.